Hepatitis C
EASL 2013: Daclatasvir plus Interferon Cures More Genotype 2/3 Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Friday, 03 May 2013 00:00
Adding the HCV NS5A inhibitor daclatasvir to pegylated interferon and ribavirin for 12 or 16 weeks led to higher response rates for previously untreated people with genotype 2 or 3 hepatitis C, according to results from the COMMAND study reported last week at the EASL International Liver Congress(EASL 2013) in Amsterdam. People with genotype 3, however, did not respond as well as those with genotype 2.
EASL 2013: Sofosbuvir + Interferon/Ribavirin Cures 90% of People with Hard-to-Treat HCV Genotypes
- Details
- Category: HCV Treatment
- Published on Friday, 03 May 2013 00:00
Adding the second-generation HCV polymerase inhibitor sofosbuvir (formerly GS-7977) to pegylated interferon plus ribavirin led to a sustained response rate of 89% for treatment-naive patients with HCV genotype 1 in the NEUTRINO study, researchers reported at the EASL International Liver Congress(EASL 2013) last week in Amsterdam. High rates were also seen for the less common genotypes 4, 5 and 6.
EASL 2013: Second-generation Protease Inhibitor Faldaprevir Cures up to 80% of Genotype 1 Hepatitis C
- Details
- Category: HCV Treatment
- Published on Monday, 29 April 2013 00:00
A second-generation HCV protease inhibitor, faldaprevir (formerly BI 201335), cured up to 80% of previously untreated people with genotype 1 hepatitis C virus infection when combined with pegylated interferon and ribavirin, Peter Ferenci of the Medical University of Vienna reported on Saturday at the EASL International Liver Congress (EASL 2013) in Amsterdam. A response gap was observed, however, between HCV subtypes 1a and 1b.
EASL 2013: Daclatasvir + Asunaprevir + BMS-791352 Looks Promising as Interferon-free Combo
- Details
- Category: HCV Treatment
- Published on Wednesday, 01 May 2013 00:00
An all-oral regimen containing 3 next-generation antivirals taken for either 12 or 24 weeks produced sustained virological response in more than 90% of previously untreated genotype 1 chronic hepatitis C patients in a Phase 2a study, according to a late-breaking poster presentation at the EASL International Liver Congress(EASL 2013) in Amsterdam.
EASL 2013: Daclatasvir + Sofosbuvir Offers Rescue Therapy after Current Standard of Care
- Details
- Category: HCV Treatment
- Published on Sunday, 28 April 2013 00:00
An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C patients who did not respond to interferon-based triple therapy using the approved HCV protease inhibitors boceprevir (Victrelis) or telaprevir (Incivek), according to a report presented at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.
EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 April 2013 00:00
Currently available triple therapies for hepatitis C using HCV protease inhibitors carry a high risk of serious side effects for patients in the most urgent need of treatment, and these individuals have only a moderate chance of being cured, according to findings from studies of telaprevir and boceprevir treatment in cirrhotic patients at liver centers in France and Austria reported last week at the 48th International Liver Congress in Amsterdam. In the Austrian study almost 1 in 10 cirrhotic patients were hospitalized with sepsis during triple therapy.
EASL 2013: MK-5172 Boosts Interferon/Ribavirin Response Regardless of IL28B Status
- Details
- Category: HCV Treatment
- Published on Saturday, 27 April 2013 00:00
The experimental HCV protease inhibitor MK-5172 increased sustained response rates to over 90% when added to pegylated interferon/ribavirin in a study of previously untreated genotype 1 hepatitis C patients, researchers reported this week at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.
EASL 2013: Hep C Quad Regimens Quashed, but Some Components Go Forward
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 April 2013 00:00
A pair of 4-drug interferon-based hepatitis C regimens worked well, but further study has been halted after a few patients experienced serious adverse events, according to a set of presentations last week at the EASL International Liver Congress (EASL 2013) this week in Amsterdam. While this type of quad regimen has little if any future, some of the component drugs remain promising.
EASL 2013: Sofosbuvir + Ribavirin Cures Most Genotype 2 Hepatitis C, but Genotype 3 Response Is Lower
- Details
- Category: HCV Treatment
- Published on Friday, 26 April 2013 00:00
A dual oral regimen containing the hepatitis C polymerase inhibitor sofosbuvir plus ribavirin produced high sustained virological rates overall, but this was driven by very good response among people with HCV genotype 2, while those with genotype 3 did not fare as well, researchers reported this week at the 48th EASL International Liver Congress (EASL 2013) in Amsterdam.
More Articles...
- EASL 2013: AbbVie Interferon-free Combination Cures Over 90% of Hepatitis C Genotype 1
- Janssen Submits Approval Requests for New Hepatitis C Drug Simeprevir
- Daclatasvir + Asunaprevir Works Well for Patients Who Cannot Use Interferon
- Gilead Submits New Hepatitis C Drug Sofosbuvir for FDA Approval
- CROI 2013: Telaprevir Triple Therapy Improves HCV Response for Black Null Responders
Web Design and Development by